Circulating innate lymphoid cells are unchanged in response to DAC HYP therapy

J Neuroimmunol. 2016 May 15:294:41-5. doi: 10.1016/j.jneuroim.2016.03.008. Epub 2016 Mar 29.

Abstract

Innate lymphoid cells (ILCs) play an important role in immunity, inflammation, and tissue remodeling and their dysregulation is implicated in autoimmune and inflammatory disorders. We analyzed the impact of daclizumab, a humanized monoclonal anti-CD25 antibody, on circulating natural killer (NK) cells and ILCs in a cohort of multiple sclerosis patients. An increase in CD56(bright) NK cells and CD56(hi)CD16(intermediate) transitional NK cells was observed. No significant change in total ILCs or major ILC subpopulations was observed. These results refine our understanding of the impact of daclizumab on innate lymphoid cell populations.

Keywords: Daclizumab; ILC; Innate lymphoid cell; NK; Natural killer.

MeSH terms

  • Antibodies, Monoclonal, Humanized / pharmacology
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antigens, CD / metabolism
  • Cohort Studies
  • Daclizumab
  • Female
  • Flow Cytometry
  • Humans
  • Immunoglobulin G / pharmacology
  • Immunoglobulin G / therapeutic use*
  • Immunosuppressive Agents / pharmacology
  • Immunosuppressive Agents / therapeutic use*
  • Killer Cells, Natural / drug effects*
  • Lymphocytes / drug effects*
  • Lymphocytes / metabolism
  • Male
  • Multiple Sclerosis / drug therapy
  • Multiple Sclerosis / pathology

Substances

  • Antibodies, Monoclonal, Humanized
  • Antigens, CD
  • Immunoglobulin G
  • Immunosuppressive Agents
  • Daclizumab